- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Patricia Coyle: Ofatumumab Has the Benefit of Being Taken at Home
The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.
Ofatumumab was recently approved to treat relapsing forms of multiple sclerosis (MS), making it a direct competitor of ocrelizumab; the biggest difference between the 2 therapies is that ofatumumab can be taken at home, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.
Transcript
Ofatumumab was recently approved for relapsing forms of multiple sclerosis. How does it fit into the treatment landscape for patients with MS?
Ofatumumab is a human anti-CD20. As an MS anti-CD20, it is a high-efficacy monoclonal agent. It will be a direct competitor for ocrelizumab, the humanized anti-CD20. Probably the biggest difference is that ofatumumab is given by a subcutaneous monthly injection every 4 weeks and can be delivered at home. This is after a 20 milligram, 3 times over 2 weeks loading dose, and then it's 20 milligrams [subcutaneously] every 4 weeks. That's in contrast to ocrelizumab, which is given intravenously every 6 months.
So, I think you have now a choice between 2 anti-CD20s that are high-efficacy, relatively safe options. One you come to an infusion center twice a year, the other you inject at home subcutaneously monthly.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
